imatinib

Examples of blood cancer drugs that are taken by mouth are thalidomide, lenalidomide and imatinib mesylate.

治疗血癌的一些口服药物的例子是沙利度胺 、 来那度胺、伊马替尼.

drugs like imatinib and sunitinib inhibit their primary target in a nanomolar concentration.

如imatinib和sunitinib这样的药物在纳摩尔浓度就抑制它们的主要靶点。

effects of imatinib mesylate in patients with chronic myeloid leukemia;

甲磺酸伊马替尼治疗慢性粒细胞白血病的循征评价更详细。

objective to study and improve the synthesis of imatinib mesylate.

目的研究和改进甲磺酸伊马替尼的合成工艺。

Objective: To explore CT in gastrointestinal stromal tumor ( GIST) and evaluation the GIST treated with molecular targeted drug Imatinib mesylate ( STI 571) by CT.

目的：探讨胃肠间质瘤（GIST）的CT表现及分子靶向药物甲磺酸伊马替尼（STI571）对胃肠间质瘤疗效的CT评价。

clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis

小剂量伊马替尼治疗慢性髓细胞白血病急变期患者的临床疗效

the advances in clinical study of imatinib mesilate

甲磺酸伊马替尼临床研究概况

imatinib is currently the most popular therapy for chronic myeloid leukemia (cml).

伊马替尼是目前治疗慢性髓细胞白血病的最普遍药物。

Complete resection is still the first choice for GIST diseases. Imatinib mesylate is the first choice for relapsing and metastatic GIST.

外科手术完整切除仍是GIST的首选治疗，甲磺酸伊马替尼是复发、转移性GIST的标准一线治疗药物。

but imatinib is known to cause heart problems in some people because it also switches off tyrosine kinases in the abl family.

但伊马替尼是众所周知的导致心脏问题，在一些人，因为它还要开关小康酪氨酸激酶在abl的家庭。

Imatinib is currently the most popular therapy for chronic myeloid leukemia ( CML ).

伊马替尼是目前治疗慢性髓细胞 白血病 的最普遍药物.

imatinib breakthrough drug for chronic myeloid leukemia, imatinib

治疗慢性粒细胞白血病新药

efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase

伊马替尼治疗慢性粒细胞白血病加速期疗效评价

clinical evaluation of imatinib mesylate in the treatment of blast-phrase chronic myeloid leukemia

甲磺酸伊马替尼治疗慢性粒细胞白血病急变期的疗效分析

the next step, says jiang is finding a drug that blocks ahi-1, which could potentially be given in combination with imatinib in the future.

江表示，下一步是找一种阻滞AHI-1的药物，这种药物可能在将来与伊马替尼联用于治疗。

analysis of abl tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients

慢性髓性白血病患者伊马替尼治疗后ABL激酶区点突变分析

background nilotinib has been shown to be a more potent inhibitor of bcr-abl than imatinib.

有研究表明与伊马替尼相比，尼罗替尼是一种更强效的BCR-ABL抑制剂。

Monitoring bcr/ abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR

实时定量RT-PCR监测慢性粒细胞白血病患者伊马替尼治疗过程中bcr/Abl mRNA水平

imatinib was re introduced in patients who had molecular relapse.

出现分子学复发的患者，再次应用伊马替尼。

Objective To evaluate the efficacy and safety of imatinib mesylate ( imatinib) in patients with Philadelphia chromosome-positive ( Ph-positive) chronic granulocytic leukemia ( CGL) in chronic phase.

目的评价甲磺酸伊马替尼治疗Ph阳性（Ph+）慢性粒细胞白血病（CML）慢性期的有效性与安全性。

resistance in the treatment for chronic myelogenous leukemia with imatinib and its management

伊马替尼治疗慢性粒细胞白血病的耐药与对策

Imatinib mesilate is a protein-tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and malignant gastrointestinal stromal tumors.

甲磺酸伊马替尼是一种蛋白质酪氨酸激酶抑制剂，用于治疗Ph染色体阳性慢性粒细胞白血病和恶性胃肠道间质肿瘤。

efficacy of imatinib mesylate in treatment of advanced gastrointestinal stromal tumors

甲磺酸伊马替尼治疗晚期胃肠道恶性间质瘤疗效的初步观察

consider using adjuvant imatinib for at least 3 (rather than 1) years in high-risk patients after resection of gist.

考虑对手术切除后的GIST高危患者应用辅助伊马替尼治疗至少3年（而不是1年）。

imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

之前和之后在慢性粒细胞白血病病态肥胖病人的胃切除甲磺酸伊马替袖子药代动力学。

objective to explore the inhibitory mechanism of imatinib mesylate on pulmonary fibrosis induced by bleomycin in mice.

目的探讨格列卫对小鼠肺纤维化的干预机制。

clinical study of chinese gastrointestinal stromal tumors patients treated with imatinib mesylate

甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究

attentive questions about the treatment of chronic myelogenous leukemia with imatinib mesylate

甲磺酸伊马替尼治疗慢性粒细胞白血病需注意的问题

The case we report is lymphocytic HES, mainly skin involvement, better response to glucocorticoid treatment, efficacy of imatinib treatment.

我们报道的该病例为淋巴细胞型HES，临床表现以皮肤受累为主，对糖皮质激素治疗反应较好，甲磺酸伊马替尼对该患者有一定疗效。

nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study

非清髓异基因造血干细胞移植联合伊马替尼治疗慢性粒细胞白血病的临床研究